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Abstract: Heart failure with preserved ejection fraction (HFpEF) is increasing in prevalence as the general 
population ages. Poorly managed heart failure symptoms of decompensated HFpEF is one of the most 
common reasons for prolonged hospital admission. The high rate of morbidity and mortality associated 
with HFpEF is compounded by a poor understanding of the underpinning pathophysiology. Randomized 
controlled trials have so far been unable to identify an evidence base for reducing morbidity and mortality in 
patients with HFpEF, although there is some evidence to support quality of life (QOL) improvement. In this 
review, we described the recent advances on the pathophysiological understanding of HFpEF, the current 
and emerging treatment strategies, and what this may mean for individual patients. Potential treatments for 
HFpEF were divided into their relative management strategies and the current evidence assessed for effect 
on HFpEF mortality, hospital admission frequency, and QOL improvement. Overall, the understanding 
of HFpEF pathophysiology is improving and has been made a priority in identifying potential therapeutic 
targets. There is growing evidence that patients with ejection fractions (EF) of less than 60% may obtain a 
mortality benefit from ACE-inhibitors, angiotensin-neprilysin inhibitors, Angiotensin Receptor Blockers, 
and Mineralocorticoid Receptor Antagonists. However, this covers only a small proportion of the HFpEF 
spectrum. Therefore, currently there are no universal treatment strategies recommended for HFpEF, and 
management should focus on an individualised approach and this should take into account the comorbidities 
of each patient. 
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Introduction
Heart failure is one of the most common reasons for 
hospital admission in the elderly population, with 
increasing prevalence and extended hospital stays as the 
population ages, with 10% affected over the age of 80 (1). 
Approximately 50% of heart failure admissions are due to 
heart failure with preserved ejection fraction (HFpEF), 
formerly known as diastolic heart failure, with the overall 
general population prevalence between 1.1–5.5% (2). An 
optimal evidence-based strategy to manage heart failure 
in this patient group is unclear and is often complicated 
by comorbidities and polypharmacy (3). Echocardiogram 
(ECHO) characteristically demonstrates an ejection fraction 
(EF) >50%. As research has previously been focussed on EF 
<40% [heart failure with reduced ejection fraction (HFrEF)], 
this precludes a HFpEF treatment strategy with a well-
founded evidence base (4). 
As HFpEF is being increasingly recognised, HFpEF 
patients are now being targeted with novel treatments 
with the potential to improve symptoms, quality of life 
(QOL), reduce hospitalization and delay progression 
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Figure 1 (A) Traditional and (B) emerging models describing pathology of HFpEF. Reproduced with permission from (Redfield et al.), 
Copyright Massachusetts Medical Society (5).
of the syndrome. Successfully improving treatment of 
this common syndrome is closely linked to the depth of 
understanding of the pathophysiology involved. This review 
describes the recent improvement in this understanding. 
We also discuss the current evidence base to support the 
treatment of HFpEF and present what the future holds with 
regard to large randomised controlled trials (RCTs). 
Methods
Clinical trials and guidelines published since 2000 were 
analysed to assess the translational benefit of HFrEF 
therapies for HFpEF as well as de novo HFpEF trials. 
Studies were included in the review if data were reported 
for patients with EF >40%, did not include congenital heart 
disease, and demonstrated evidence of diastolic failure on 
ECHO, which is synonymous with HFpEF. 
Pathophysiology
Previously described as diastolic heart failure, HFpEF is a 
distinct functional deficit in heart function during diastole. 
This is when the heart muscle contracts normally, hence 
normal ejection fraction, but does not adequately relax 
to allow normal filling during diastole. This results in an 
increased left ventricular end diastolic pressure (LVEDP), 
which is the hallmark of HFpEF. Despite the general 
understanding of HFpEF at a functional level, there are 
limited pathological targets for disease modification. The 
search for therapeutic targets has led to the development 
of the traditional and emerging pathological models of 
HFpEF (Figure 1) (5). 
Historically, the traditional model explains that HFpEF 
stems from either systemic hypertension or vascular 
dysfunction which then further leads to concentric 
hypertrophy of LV, diastolic dysfunction and fibrosis in 
the left ventricle (Figure 1A). This would cause left atrial 
hypertension, bringing about remodelling and both systolic 
and diastolic dysfunction in the left atrium. At this stage, 
atrial fibrillation and pulmonary hypertension can develop, 
leading to similar remodelling and dysfunction in the right 
side of the heart, throughout all of the cardiac cycle. This 
was demonstrated in 2019 and was most exaggerated during 
exercise states (5,6).
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The emerging model (Figure 1B) postulates that HFpEF 
is the reaction from coexisting proinflammatory conditions, 
i.e., obesity, hypertension, diabetes mellitus etc., giving 
rise to systemic microvascular endothelial inflammation. 
At the molecular level, these comorbidities cause reduction 
in the levels of nitric oxide (NO) and cyclic guanosine 
monophosphate (cGMP), cascading to events such as 
hypertrophy and increased stiffness in cardiomyocytes, 
fibrosis and vascular dysfunction. Ultimately, global cardiac 
remodelling and dysfunction take place together resulting 
in increased LVEDP (5). 
Although treatment for HFrEF is similar regardless of 
heterogeneous aetiology (e.g., ischaemic vs. hypertensive 
pathology), the models described in Figure 1 illustrate 
specific targets that form part of a bespoke approach to 
HFpEF, which also may require alterations according to 
phenotype and comorbidities. For example, in heart failure 
female sex is a non-modifiable risk-factor, but obesity may 
be a modifiable factor in the development of hypertension, 
and ultimately HFpEF (7). Therefore, it is probable that 
this individualised approach will be required, leading to 
difficulties in clinical trial design (8).
A study by Obokata et al. in 2017 aimed to demonstrate 
this via Echocardiography and invasive haemodynamic 
measurements during exercise. This study recruited 99 
obese (BMI >35 kg/m2) and 96 non-obese (BMI <30 kg/m2) 
who had HFpEF, with 71 healthy non-obese volunteers as 
controls. Results showed that obese patients demonstrated 
increased in LV remodelling, plasma volume, biventricular 
filling pressures, and resultant RV dysfunction. In addition, 
increased heart volumes and pericardial fat deposition 
resulted in increased pericardial restraint, and therefore 
worsened diastolic filling (9). This was further supported 
by Parasuraman et al. who demonstrated that increased bi-
ventricular filling pressures, demonstrated by a flattened 
interventricular septum on ECHO, results in a reduced 
utilisation of the innate Frank-Starling mechanism in 
periods of exercise, leading to impaired diastolic function, 
and resultant reduced exercise tolerance (6). Thus, impaired 
diastolic filling of the left ventricle may have multiple 
aetiologies, each with a different solution. For example, 
whilst fluid overload requires diuretics, obesity may require 
supervised exercise regimes.
Diagnosis of HFpEF
HFpEF is defined as symptoms synonymous with heart 
failure resulting from impaired ventricular relaxation during 
diastole. Amongst other measurements, it manifests as 
increased LVEDP on ECHO.
Table 1 describes the criteria employed by the ESC and 
AHA/HFSA. The most significant difference is the cut-off 
for LVEF, with AHA/HFSA stating that LVEF greater than 
40% with evidence of diastolic dysfunction is consistent 
with HFpEF, whereas, ESC dictates that LVEF should be 
greater than 50% with evidence of diastolic dysfunction, 
and LVEF of 40–49% are to be treated as a ‘grey area’, and 
essentially creating a buffer between the two diagnoses (10). 
Consequently, physicians and scientists have consistent 
difficulty in diagnosing HFpEF or designing optimal 
clinical trials due to different diagnostic criteria and variable 
patient phenotypes/comorbidities evident by different 
eligibility criteria observed in most of the HFpEF trials. 
Other than LVEF, echocardiography can include 
multiple other parameters including LVMI, LAVI, and E/e’ 
Table 1 Relative HFpEF criteria (2,10)
ESC criteria for HFpEF (in 2016)
NYHA associated HF symptoms
Elevated BNP and/or NT-proBNP
Echocardiography
LVH
LAE
LVEF ≥50%
LVMI >115 g/m2 (>95 g/m2 females)
LAVI >34 mL/m2
E/e’ ratio >13
AHA/HFSA-criteria for HFpEF (in 2017)
NYHA associated HF symptoms
Echocardiography
cLVH
LAE
LVEF ≥40%
Evidence of LV diastolic dysfunction
AHA, American Heart Association; cLVH, concentric left 
ventricular hypertrophy; E/e’, mitral inflow velocity/early diastolic 
velocity of mitral annulus; ESC, European Society of Cardiology; 
HFSA, Heart Failure Society of America; LAE, left atrial 
enlargement; LAVI, left atrial volume index; LVEF, left ventricular 
ejection fraction; LVH, left ventricular hypertrophy; LVMI, left 
ventricular mass index; NYHA, New York Heart Association. 
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ratio, the latter of which replaces E/A ratio due to increased 
accuracy during assessment at rest, although E/e’ is less 
favourable in concomitant systolic failure. However, it 
should be considered that the echocardiographic difference 
in LVEF in HFrEF and HFpEF even by the most stringent 
criteria is 10%, which in a study in 2018 demonstrated that 
the inter-operator difference in measuring ejection fractions 
(EF) was between 0 and 10% with an average variation of 
4.27%. A difference that may increase in size when more 
complicated measurements are attempted (11).
A useful tool for physicians with limited access to invasive 
testing was developed by Reddy et al. This is a validated 
scoring tool (H2FpEF) to differentiate HFpEF from non-
cardiac causes of dyspnoea. This can direct the need for 
additional referrals/tests, as well as prompt the requirement 
to consider a different evidence base from HFrEF (12).
HFpEF treatment strategies 
Volume overload
Loop diuretics
The administration of diuretics in the management of 
HFpEF aims to improve the symptoms of heart failure, 
namely oedema and dyspnoea. In 2008, the Hong Kong 
Diastolic Heart Failure Study involving 150 patients with 
LVEF >45% who were randomised to either Diuretics 
alone, diuretics plus irbesartan, or diuretics plus ramipril. 
Outcome measures were QOL, 6-minute walk test, and 
echocardiographic measures of cardiac preload. This study 
found that the isolated use of diuretic was associated with 
a significant improvement of symptoms and QOL but had 
no mortality benefit or reduction in HF hospitalization. 
In addition, diuretics in combination with Irbesartan/
Ramipril marginally improved both LV systolic and 
diastolic longitudinal function, and lowered N-terminal pro 
b-type natriuretic peptide (NT-proBNP) over a period of 
1 year (13). 
This was in agreement with a 2002 meta-analysis of 
RCTs of diuretic therapy in heart failure by Faris et al. 
Eighteen trials were included which showed a marked 
reduction in symptoms across the spectrum of EF (mean 
46%) (P=0.007) (14).
Mineralocorticoid receptor antagonists (MRA)
MRA’s have an existing evidence base for treatment of 
HFrEF and demonstrate good symptom control and 
QOL improvement, some of which has recently been 
demonstrated in the TOPCAT trial, a trial which was 
designed to assess the efficacy of Spironolactone in HFpEF 
by the composite outcome of reduced CV mortality and 
cardiac arrest, with a secondary outcome of heart failure 
related hospital admissions. However, there has been no 
evidence to support the reduction of mortality/morbidity 
in HFpEF. Coupled with the undesirable side-effects such 
as hyperkalaemia, renal dysfunction, post-menopausal 
bleeding, and gynaecomastia, has resulted in MRA’s falling 
out of favour (15). 
The TOPCAT trial enrolled 3,445 participants 
worldwide who were randomised to treatment (n=1,722) 
or placebo (n=1,723), with inclusion criteria modelled 
around the American Heart Association (AHA) definition 
of HFpEF. TOPCAT did not demonstrate improvement in 
the composite outcomes, but showed a small reduction in 
HF hospital admissions (NNT =45) (15). 
Subgroup analyses demonstrated a benefit in patients 
with elevated brain natriuretic peptide (BNP) (hazard 
ratio, 0.65; 95% CI, 0.49 to 0.87; P=0.003). The authors 
speculate that this could be a chance finding or could be 
due to differences in baseline characteristics between these 
two strata. BNP has been shown to be associated with left 
ventricular remodelling and potentially an early marker of 
diastolic dysfunction. Therefore, BNP measurement may 
be an optimal feature in future study protocols (15,16). 
Of note, TOPCAT trial used less stringent AHA criteria, 
and post-HOC analysis indicated that only 34% of the 
included patients would meet the more stringent European 
Society of Cardiology criteria.  
Kurrelmeyer et al. conducted a study with only 48 
elderly female patients (age >70) and was powered for 
HF symptoms (NYHA class I–IV) and modification of 
6-minute walk distance. Overall, the clinical composite 
score, encompassing NYHA level, and a rating on a 3-point 
Likert scale indicated an improvement with Spironolactone, 
however, no improvement in 6-minute walk distance was 
observed. This supports that Spironolactone stabilised the 
symptoms/clinical decline in this subset of elderly females. 
Although this study was not powered, Echocardiography 
also demonstrated improvement in transmitral Doppler 
early filling velocity to tissue Doppler early diastolic mitral 
annular velocity ratio (E/e’) and therefore reduced filling 
pressures in the left ventricle. Furthermore, a reduction 
in the level of type III procollagen levels were observed, 
potentially indicating a reduction in myocardial fibrosis and 
resultant remodelling (17). 
The currently ongoing SPIRRIT trial  (due for 
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completion in 2022) is powered to assess morbidity and 
mortality benefit of Spironolactone in HFpEF. The trial is 
recruiting 3,200 patients across Sweden and the USA with 
an elevated BNP, but also includes patients with moderately 
reduced EF at 40–49% (10).
Rate control and management of AF
Beta-blockers 
Beta-blockers have long been demonstrated as having a 
positive benefit in HFrEF through reducing heart rate, 
reducing myocardial oxygen demand, improving diastolic 
filling time, as well as LV remodelling. However, there is 
minimal evidence to suggest that these benefits translate to 
HFpEF. Although there have been no large RCTs of beta-
blockers in HFpEF patients, the OPTIMISE-HF registry 
in the USA to track the outcomes of 7,154 heart failure 
patients shed some light on the matter. Compared with the 
significant benefit for HFrEF, this study found that beta-
blockers were not associated with any improvement in 
outcome for HFpEF (18). 
A meta-analysis carried out in 2015 included 15 
observational studies and two RCTs with a total of 27,099 
HFpEF patients with EF >40%. Overall, the included 
studies were underpowered to significantly detect the 
endpoints (RR 0.94, P=0.718). A random-effects model 
was utilised to assess the role of beta-blockers on all-
cause mortality and HF hospitalization. The study found 
no benefit in mortality (RR 0.94, P=0.718) but significant 
benefit for HF hospitalisation (RR 0.81, P<0.001). 
Subgroup analysis also suggested that this effect was also 
limited to patients under 75 (RR 0.92 vs. 0.64, P=0.81 vs. 
0.001) (19).
Recently Lam et al. (in 2018), reported the effect of 
beta-blocker use in heart failure patients with an ejection 
fraction >50% and heart rate >70 beats per minute. A total 
of 4,537 patients were identified from the OPTIMIZE-HF 
registry with no contraindications for beta blockade, with 
2,592 participants in the treatment arm; 730 patients in the 
treatment arm received high dose beta blockade (Atenolol 
>100 mg, Carvedilol >50 mg, Metoprolol >200 mg, 
or Bisoprolol >10 mg), and 1,740 received no treatment 
(205 returned no data). Follow-up was over 6 years (median 
2.8 years) and the trial demonstrated a significant 14% risk 
reduction for combined all cause readmission and mortality 
P=0.027) (20). 
Cleland et al. performed a meta-analysis of 11 clinical 
trials involving 17,312 patients evaluating all spectra of EF. 
Included in this analysis was 244 patients with EF >50% 
where beta blockade provided no benefit in patients who 
were in either sinus rhythm or atrial fibrillation. However, 
this analysis lacked the power to detect a significant change 
for the HFpEF group but showed clinical improvements for 
EF <50% (21).
Ivabradine
Ivabradine is a rate control agent that acts on the If (known 
as funny current channel) in the sino-atrial node and is only 
employed when the patient is in sinus rhythm. It can be 
used as an alternative option when patients are unable to 
tolerate beta blockade and has shown a reproducible benefit 
in HFrEF (22). 
The EDIFY trial published in 2017 was a randomized, 
double-blind, placebo-controlled trial assessed whether 
heart rate (HR) reduction with ivabradine improves cardiac 
function in HFpEF. The hypothesis was a reduction in heart 
rate would result in the reduction in LVEDP, as reflected by 
the E/e’ ratio on echocardiography. Treatment was titrated 
until optimal HR of between 50–60 bpm was achieved. 
The combined primary endpoints were E/e’ ratio, total 
distance on 6-minute walk test, and plasma NT-proBNP 
concentration, and these were measured at baseline, 
2 months, and 8 months. Despite an average reduction 
in HR or 13 bpm, the study found no evidence of 
improvement of diastolic dysfunction or exercise capacity 
nor significant differences in adverse events (23). 
Digoxin
Digoxin is a cardiac glycoside which exerts negative 
chronotropy and positive inotropy in the treatment of atrial 
fibrillation. It improves cardiac output, ejection fraction, 
and reduces filling pressures and pulmonary capillary wedge 
pressure. It is theorised that these effects may translate to a 
benefit in HFpEF.
Pau et al. (in 2019) evaluated the risk of all-cause 
mortality and composite outcome of mortality and HF 
admissions within 1 year. The study included 1,833 patients 
with HFpEF who were >70 years old and had EF >50%. 
The Digoxin group demonstrated a significant increased 
mortality (HR 1.46, P=0.001) and HF admissions (HR 1.35, 
P=0.001), this effect was pronounced at lower heart rates. 
Overall, Digoxin was shown to have a negative prognostic 
effect for HR <90, and a neutral effect on higher HR in 
patients with HFpEF (24).
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Management of hypertension
Renin-angiotensin-aldosterone system (RAAS) 
inhibitors
ACE inhibitors and ARBs are currently used to treat 
comorbidities such as chronic kidney disease (CKD) with 
proteinuria and also have a proven benefit in LV reverse 
remodelling in HFrEF. 
The PEP-CHF trial was a placebo controlled RCT 
assessing 850 patients with LVEF ≥40%, with symptomatic 
HF,  and  demonstra ted  d ia s to l i c  dys funct ion  on 
echocardiography, were randomised to receive Perindopril 
or Placebo. After 2.1 years follow-up there was no 
statistically significant difference in all-cause mortality or 
cardiovascular hospitalisation (P=0.35). Poor recruitment 
and retention of study participants rendered this study with 
insufficient power to detect a difference in the primary 
endpoint (25).
The efficacy of ARBs was assessed in the I-PRESERVE 
(Irbesartan) and CHARM-preserved (Candesartan). 
I-PRESERVE enrolled 4,128 patients >60 years old, NYHA 
Class II–IV, and an EF >45%, who were randomly assigned 
to receive Irbesartan 300 mg or placebo. The study failed to 
meet any of the primary endpoints (P=0.54). The CHARM 
study recruited 3,023 patients with LVEF >40% and NYHA 
II–IV who were randomised to either Candesartan 32 mg 
or Placebo. Candesartan showed a moderate reduction in 
HF hospitalisations (P=0.017) but no difference in the other 
endpoints (26,27).
Nitrate 
Nitrates are a regular feature in the management of angina, 
and heart failure which does not respond to conventional 
therapy. In HFpEF, a potential therapeutic target could be 
to reduce the bi-ventricular filling pressures by reducing 
cardiac preload. Additionally, animal models have suggested 
that nitrates may have a role in assisting ventricular 
relaxation during diastole, and therefore, a reduction in 
LVEDP (28). 
The NEAT-HFpEF trial recruited 110 patients with 
HFpEF patients (LVEF >50%) and compared placebo to 
Isosorbide Mononitrate (titrated from 30 to 60 mg, and then 
120 mg daily). Effect was assessed by activity levels, QOL 
scores, 6-minute walk distance, and levels of NT-proBNP, 
for all dosages. Activity levels were lower in the treatment 
group, and this effect worsened with increased dosage. 
There was no significant difference in the other outcomes. 
The 2017 Heart Failure Focussed Update from ACC/AHA/
HFSA suggested no advantage of adding nitrates to a heart 
failure treatment regime, a recommendation based on the 
results of this trial (29).
Targeted nitrate could potentially be used in HFpEF to 
increase exercise intolerance and is emerging as a possible 
target to optimize haemodynamics and reduce bi-ventricular 
interaction during stress. Borlaug et al. assessed 105 patients 
with HFpEF patients with EF >50% (mean EF 61%), to 
assess whether inhaled Nitrite improved exercise tolerance, 
NT-proBNP levels, oxygen consumption, QOL score, 
and cardiac filling pressures (E/e’). A Nitrite compound 
was selected as it is more readily converted to the active 
Nitric Oxide in hypoxic/acidotic states and is converted in 
a 1-stage reaction leading to a rapid effect. This crossover 
trial randomised patients to 1 of 2 treatment groups (placebo 
first with crossover to nitrite, or vice versa). A washout 
period of two weeks was employed between crossover to 
ensure accurate data (30).
This study, however, failed to meet any of the end points, 
including a failure to reduce LVEDP as represented by E/
e’ ratio. This was theorised to be in part due to the short 
acting nature of the nitrite compound, which is unable to 
achieve significant changes is cardiac function. In addition, 
the large percentage of obese patients in the trial (75%) may 
indicate that the symptoms of HFpEF may be due to body 
habitus exerting a mass effect, rather than intrinsic changes 
in cardiac myocyte function (7). Further indicating the 
heterogeneity of HFpEF, and the need to stratify patients 
according to comorbidities/phenotypes/genotypes to obtain 
accurate data (30). 
Further clinical trials to assess the role of Nitrates in 
HFpEF are ongoing and are due to report in 2020. These 
include INDIE-HFpEF and KNO3CK OUT HFpEF 
trials.
Calcium channel blockers
There is minimal trial data available for the use of Calcium 
Channel Blockers (CCBs) assessing improvements in 
diastolic function and symptoms in HFpEF.
In 2014, Patel et al. performed propensity analysis 
on 1,620 patients obtained from the OPTIMIZE-
HF registry, who had a HFpEF and no prior history of 
CCB prescription. Two groups of 810 patients allocated 
to CCB treatment were matched for age, and average 
EF of 56%. They were assessed for differences in HF/
non-HF hospitalisation rates, and all-cause mortality. 
No significant difference was found for all endpoints 
(HR: 1.05) (31).
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Novel medications
Angiotensin-neprilysin inhibitor (Entresto)
Entresto is the brand name for the Angiotensin—Neprilysin 
inhibitor which has demonstrated such efficacy in HFrEF, 
the PARADIGM-HF trial was halted early. This drug is a 
twice-a-day medicine that aims to improve overall cardiac 
function by enhancing the protective neurohormonal 
systems (natriuretic peptide system) while simultaneously 
inhibiting the harmful effects of the overactive renin-
angiotensin-aldosterone system (RAAS) (29). Other 
common heart failure medicines, namely angiotensin 
converting enzyme (ACE) inhibitors and angiotensin II 
receptor blockers (ARBs), only block the harmful effects 
of the overactive RAAS and have shown to assist LV 
remodelling. Entresto contains the Neprilysin inhibitor 
sacubitril and the ARB valsartan (32,33).
In 2014, the PARADIGM-HF trial demonstrated 
superiority of Entresto vs. Enalapril alone for HFrEF 
with NYHA class II–IV symptoms. The benefits included 
a reduction in HF hospitalisations, as well as all-cause 
mortality. Physiologically, this resulted in a reduction 
in NT-proBNP in conjunction with LV/LA reverse 
remodelling and improved NYHA symptoms (32).
In response to the potential benefit to HFpEF patients, 
the PARAGON-HF randomized, double blind trial was 
completed in August 2019 and was the largest Phase III 
trial to date that aimed to demonstrate a similar benefit 
to HFrEF. Inclusion criteria of age >50, HFpEF (LVEF 
>45%), NYHA II-IV symptoms on diuretics, evidence of 
LAE or LVH on Echo and an associated elevation of NT-
proBNP. It demonstrated an improvement in NT-proBNP 
level and NYHA class at 12 and 26 weeks respectively. 
Additionally, it excluded any patient who had a previous 
EF <40% recorded at any time. A total of 4,822 patients 
randomised to Entresto or Valsartan and were followed-
up for 35 months on average. The study was powered 
at 95% to detect a CV death reduction of 10% and HF 
hospitalisation of 30%, which was narrowly missed (P=0.06). 
Subgroup analysis demonstrated a potential positive effect 
for females (HR 0.73, 95% CI: 0.59–0.70, P=0.06), and 
LVEF <57% (HR 0.78, 95% CI: 0.64–0.95, P=0.03). 
No benefit was shown for EF >57% (HR 1.00, 95% CI: 
0.81–1.23, P=0.02). In addition, the Entresto group had a 
reduced incidence of renal dysfunction (HR 0.50, 95% CI: 
0.33–0.77, P=0.002) (34).
Phosphodiesterase-5 inhibitors
The PDE-5 inhibitor Sildenafil is an established treatment 
for management of primary pulmonary hypertension. It 
was postulated that by reducing pulmonary pressures, it 
would lead to reduced bi-ventricular interdependence and 
aid relaxation in diastole, resulting in reduced LVEDP. This 
is due to evidence of worsening outcomes in HFpEF with 
associated pulmonary hypertension and right ventricular 
failure secondary to increased afterload. It has also been 
suggested that Sildenafil may reverse cardiomyocyte 
hypertrophy where PDE-5 proteins are overexpressed in 
animal models (35,36). 
Marco et al. assessed 44 HFpEF patients with pulmonary 
hypertension (PASP >40 mmHg), with HFpEF (LVEF 
>50%), and diastolic dysfunction were randomly assigned 
in a 1:1 ratio to either a placebo or sildenafil (50 mg 
tds). Measurements were made via invasive cardiac 
catheterisation for pulmonary pressures and RV function, 
and echocardiography to assess diastolic dysfunction. 
Follow-up at 12 months demonstrated improvement in 
hypertrophy, LV diastolic function, and reduced pulmonary 
pressures in the sildenafil group (P=0.01). There were no 
improvements in QOL outcomes (37).
RELAX trial involved 216 HFpEF (EF >50%) patients 
who were given Sildenafil after baseline invasive and 
echocardiographic measurements. Treatment effect was 
assessed at 24 weeks. Outcomes included effect on QOL, 
exercise capacity, left ventricular remodelling, diastolic 
function, and pulmonary artery pressures. At 24 weeks, 
there was no significant difference in exercise capacity or 
clinical status. There was also no significant difference in 
echocardiographic or cardiac MRI parameters. Notably, 
worsening of renal function in the treatment group was 
statistically significant, and this resulted in increases in NT-
proBNP, suggesting that the associated renal dysfunction 
was clinically significant (38).
Hoendermis et al. assessed 52 patients in a single centre 
RCT, with pulmonary hypertension secondary to HFpEF 
(EF >45%) who were randomised 1:1 to either Sildenafil 
60mg or placebo. No significant benefit was demonstrated 
on pulmonary pressures, cardiac output, peak oxygen 
consumption, and adverse events were similar between the 
groups (39). 
Overall, Sildenafil appears to demonstrate a small effect 
on echocardiographic and invasive measurements, but no 
effect on clinical status or QOL.
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Others
Statins
Statins are HMG-CoA Reductase inhibitors and are 
primarily used as lipid lowering therapies as part of 
ischaemic heart disease and stroke prevention. There have 
been no randomized clinical trials assessing the potential 
of Statin therapy in HFpEF, and this may be in part due to 
the drug being off-patent. However, several observational 
studies have demonstrated potential mortality benefit in this 
subset of patients.
In cardiac myocytes ,  s tat ins  inhibit  guanosine 
triphosphate-binding protein and Rho-Kinase activity, 
theorised to be a key signalling pathway in ventricular 
remodelling post MI. Therefore, this effect of statins 
is independent to the cardiovascular risk modification 
related to LDL cholesterol. Suppression of LVH and LV 
remodelling was previously demonstrated in experimental 
models in mice (40).
Fukuta et al. (in 2005) studied a total of 137 patients 
in total with EF >50% were separated into groups who 
received statins (n=68) and who did not (n=69). After a mean 
follow-up of 21 months (±12), the statin group demonstrated 
a substantial improvement in survival (HR 0.22, 95% CI: 
0.07–0.64, P=0.006). The patient numbers were small 
in this study, but baseline ECHO markers of diastolic 
function were near identical between the groups (41). 
This study was followed in 2015 as a meta-analysis of 
prospective observational studies with the use of propensity 
score analyses and included 4 studies (3 additional studies 
added to the Fukata 2005) and a total of 5,536 patients 
(2,768 on statins). The pooled analysis allied closely with 
the previous findings in that the statin group demonstrated 
a reduced mortality (OR 0.69, P=0.03) (41,42).
Marume et al. (in 2019), assess the efficacy of statin 
therapy in patients with HFpEF but in the absence of 
coronary artery disease (CAD). This study was based on the 
hypothesis that the main benefit of statins in HFpEF was 
the prevention of atherosclerosis and therefore a reduction 
in the ischaemia related dysfunction. A total of 414 with 
HFpEF without CAD were selected for propensity analysis 
and were selected from a nationwide HFpEF registry 
(JASPER registry). The statin group contained 81 patients 
with 333 in non-statin group, and follow-up was 25 months. 
The statin group showed improved all-cause mortality, non-
cardiac death, or HF rehospitalisation. In particular 3-year 
mortality was improved (HR 0.21, 95% CI: 0.06–0.72, 
P=0.014). However, there was no significant difference 
in cardiac related deaths, and the mortality benefits of 
statins did not have a statistically significant interaction 
with cholesterol level or heart failure severity. In addition, 
the statin group had slightly higher echocardiographic 
indicators of diastolic failure at baseline (43).
Non-pharmacological management
Cardiac rehabilitation
Edelmann et al. considered exercise training to improve 
exercise capacity and diastolic function in patients with 
HFpEF. A total of 64 patients underwent 2:1 randomisation 
to receive supervised endurance and resistance training plus 
usual care (n=44) against usual care alone. Primary endpoint 
was a change in peak VO2 (a measure of muscular oxidative 
function) at 3 months, with secondary endpoints being 
cardiac structure, diastolic function [E/e’ and left atrial 
volume index (LAVi)], and QOL. This study demonstrated 
that exercise training improved exercise capacity, diastolic 
function and QOL with all measurements within 95% CI 
range, P=0.001. Improvement in these markers may be as 
a direct effect of exercise, or indirect benefits as a result of 
weight loss (44).
Conclusions
As evident by our findings, an effective pharmacological 
treatment that reduces morality in HFpEF remains elusive, 
with no RCTs demonstrating a clear mortality benefit for 
any drug class. Evidence provided in post-hoc subgroup 
analysis identified a potential mortality benefit for MRAs 
and RAAS inhibitors. Both the TOPCAT (Spironolactone) 
and CHARM (Valsartan) studies indicate a CV mortality 
benefit in LVEF <60%, with increasing benefit in the lower 
LVEF ranges. This finding extends to the PARAGON-
HF (Entresto) trial, where LVEF <57% were associated 
with improvements in outcome. This may assist medication 
choice in HFpEF patients with concomitant fluid overload 
and/or hypertension, but only extends to a small fraction 
of the patient population with EF <60%. A further RCT 
assessment of MRAs (SPIRRIT-HFpEF trial) is due for 
completion in 2021 (8,15,34). 
As statins are a less expensive and readily available 
medication which patients often already take, the 
analysis of statin trials offers an interesting treatment 
consideration other than cardiovascular or stroke risk. It 
also focussed on the pro-inflammatory ‘emerging model’ 
of HFpEF pathology. Three small trials assessing statins 
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all demonstrated mortality benefits (HR 0.21, 0.22, and 
OR 0.69), although the trials had small patient numbers. 
Nitrates do not improve function or symptoms in HFpEF 
in the absence of limiting ischaemic heart disease, and 
although PDE-5 inhibitors demonstrate a small effect on 
echocardiography and invasive measurements, they have no 
effect on QOL or mortality (28-30,37-39,40-43). 
Importantly, in all patient subgroups, the utility of 
maintaining mobility and regular exercise should not be 
understated and may improve diastolic heart function and 
QOL. There are no large-scale assessments of exercise 
therapy, but small trials have shown a clear benefit when 
compared to standard HF care (44). This approach may be 
strongly beneficial in particular phenotypes (7,9).
Also, in comparison with HFrEF, HFpEF patients are 
more likely to die from non-cardiovascular events (10). 
Thus, it is advisable to screen patients who are diagnosed 
with HFpEF for associated comorbidities and undertake 
an individualised approach to treatment. In addition, the 
frailest patients who already have a reduced QOL, an 
individualised goal-directed approach with a strong focus 
on symptom improvement may be the optimal strategy. 
In personalising treatment, caution should be exercised in 
the use of diuretics and beta-blockers in the frail population, 
as excessively reducing preload can lead to LV underfilling 
and resultant fall in cardiac output. Beta blockers are often 
employed in coexisting IHD or AF and can magnify this 
effect by inhibiting the chronotropic response and thus, 
significantly increasing falls risk or end organ damage.
Potential reasons for equivocal or failed trials include 
trial design (e.g., different demographics, aetiologies, 
comorbidities, response to therapies, poor recruitment, 
and high drop-out rate); there is no global consensus on 
the definition of HFpEF; there is limited stratification 
of subgroups in HFpEF patients in RCTs; the lack of a 
standardised approach to admitting patients for HF across 
different healthcare systems. For future trial design, it would 
likely be beneficial if HFpEF patients were subcategorized 
into more mechanistically homogenous, discrete genotypes, 
phenotypes, and aetiologies (i.e., race, age, genetic, HTN, 
DM, AF, COPD, valvular heart disease, frailty). This could 
be in the form of a carefully matched case-control design to 
ensure a relevant stratification of the genotype/phenotypes. 
Although there is now a renewed push for high quality 
evidence to support the treatment of HFpEF, this must 
be done with a clear definition and a stringent trial 
design to ensure reliable results within these subgroups. 
Improvements in understanding the pathophysiology 
involved will improve the accuracy of results and may lead 
to novel treatment agents to ameliorate the high morbidity 
and mortality burden and supersede the need to assess 
existing therapies that have failed thus far to demonstrate 
benefit. 
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